I gave up artificial food dyes for a month. It was harder than I thought.
As I whirred my way through my fridge, pantry and medicine cabinet, I was alarmed by how many of my kids' go-tos — mostly treats, but also things like pickles and Tylenol — include synthetic additives like Red Dye No. 40 and Green Dye No. 3. What surprised me even more, though, was the flip side: There was a whole category of neon kid foods I had assumed I'd need to eliminate (mac and cheese, Goldfish crackers, etc.) that turned out to have no artificial food dyes at all thanks to naturally bright colorants like turmeric. Phew.
Why try to avoid or eliminate synthetic food dyes in the first place? Earlier this year, the Food and Drug Administration announced that it would ban the dye known as Red No. 3, which is petroleum-based and found in common foods like frosting, fruit cocktail and gummies. Health Secretary Robert F. Kennedy Jr. recently took it a step further, announcing that the FDA and the Department of Health and Human Services will eliminate all petroleum-based artificial food dyes from foods sold in the U.S.
The primary concern with these dyes is that consumption of them has been linked to behavioral problems in some children, according to analysis from the State of California. Then there's the issue that, while a dye like Red 40, for example, is not currently listed as a carcinogen itself, it does include benzene, which has been linked to increased cancer risk.
Plus, these dyes are derived from petroleum. In an era of omnipresent and often ingested microplastics, did I really want to be feeding my kids this stuff? Of course not, I thought. But I wasn't sure how feasible it would be to swap them all out.
Where to start? The Center for Science in the Public Interest shares a starter list of common foods that include synthetic dyes, so I stormed through my kitchen and bathroom in search of those and to read all the other labels I encountered. Then I set out for our local Kroger to find the necessary swaps and was only somewhat successful. Since dye-free alternatives weren't always readily available there, I also had to squeeze in a trip to the health food store.
Then there are all the difficulties of sourcing dye-free in the wild, like at the gas station next to my son's taekwondo class, where he often grabs a Gatorade. Most notably, our dye-free month coincided with a family trip to North Carolina, and travel definitely put the difficulty of finding alternatives into perspective. It also meant passing up this pretty (but dye-enhanced) sea glass candy.
Here are the main food dye culprits I discovered in my family's food rotation, and what I ended up replacing them with.
In my research, I discovered that most of the major pickle companies, including Mt. Olive, do offer a dye-free version, but only the Vlasic one was available at my Kroger. I was interested in figuring out whether the dye-free versions would all be more expensive, as NPR's recent reporting seems to indicate, but it was impossible to find an exact dye-free/with-dye comparison within the same brand at the same store. Among Target's wide variety of Vlasic options, price variations are only a matter of cents. So the main reason to skip the swap seems to be if you really, really want your pickles to be neon.
Surprise! Who knew my '90s favorite kid drink, Capri Sun, was actually dye-free? Whether we were headed to sports practice or the airport, juice-like drinks marketed to kids, from a rainbow of Gatorades to Sunny D (which includes Yellow 5 and Yellow 6), were items that kept popping up during this experiment. Luckily, my sons were not at all fazed by the (equally sugary, I'm sure) dye-free swap options. The Bubly Burst was a particular hit; it's colored with carrot juice concentrate and is compellingly bright pink.
In this mom's opinion, Lily's gummies, colored with vegetable dyes, taste better. The downsides were price (Lily's gummies were $2.50 for one measly pouch at Kroger, whereas Welch's cost $6 for 22 pouches) and availability: Welch's fruit snacks are my kids' favorites to grab at the airport to help their ears pop during takeoff and landing. Sadly, the likes of Lily's have not expanded to the national airport market (yet!). Lily's gummy bears also softened the blow of having to ditch our stash of Blue 1-enhanced Airheads.
We have been potty training my youngest, and M&Ms have been a hugely helpful tiny treat. My little one gets two M&Ms when he pees in the potty, three for a poop. I am not above a bribe that makes my life easier! He did not notice at ALL when I swapped his reward, and I'm now obsessed with these better-tasting (to me), off-brand, all-natural alternatives. They're colored using vegetables, and they even use real vanilla. But alas, this was a swap that required a trip to the natural foods store, and I couldn't find them at the airport.
The spicy El Yucateca was a stealth culprit; I was surprised to see 'Yellow 5 and Blue 1' listed in the ingredients list. Why is it necessary to dye green peppers green? Luckily, Marie Sharp's variation made for a tasty, dye-free substitute.
Ah, the problematic pièce de résistance of the food dye swap-out. My kids love grape Tylenol, but it's colored with Red 33 and Blue 1. When I got the dye-free kind and offered it to my son after a dental procedure, the prospect of sucking down non-purple medication elicited plenty of whines and a lot of pushback. Which led me to …
I know I'm not alone as a conscientious yet kinda lazy parent. And while this swap-out experiment was, for the most part, straightforward, the somewhat difficult parts of it (travel, Tylenol) left me asking: How worried do I really have to be about these food dyes? Do I have to keep pushing dye-free Tylenol if the bright purple version makes my life easier?
'It's not a deal breaker at all,' Jamie Alan, an associate professor in the Department of Pharmacology and Toxicology at Michigan State University, tells Yahoo Life. When it comes to synthetic food dyes, 'a small, limited dose will likely have no effects on the vast majority of children.'
The primary risk to watch for, Alan explains, is the one found in the California report: the fact that 'some food dyes have been linked to neurobehavioral issues and hyperactivity.' But that's only in some kids, and as always it's important to make decisions based on your own individual child's health and behavior (and in tandem with your child's medical care providers) rather than based on what might work best for another child — or worse, what you read on some blog.
Alan provides a few helpful suggestions for parents and other individuals who do want to reduce artificial food dyes in their kitchens, bathroom cabinets and lives overall. The first step? Actually reading what you're about to buy or consume. 'Checking the label is important,' Alan says. One smart hack is shopping imported (easier said than done during 2025 tariff days, we know), since 'many other countries have already banned some of these dyes," Alan notes. "Checking the aisles for imported products, like drinks and candies, might be useful."
Overall, your best bet is to pay attention to both the ingredients your family consumes and your child's behavior — something we parents should probably be doing anyway, food dyes or no food dyes. But don't stress too much about it. 'Not all children are sensitive to these dyes,' Alan reiterates, 'but there are some children who are very sensitive to these dyes when consumed.'
As for me, I'm 100% going to stick with the vast majority of the food swaps I stocked up on in my kitchen — all those treats and pickles taste just as good without the additives. But I'll likely go back to buying the purple Tylenol.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Los Angeles Times
40 minutes ago
- Los Angeles Times
Here's how to get GLP-1 drugs covered by employer health insurance
While the new anti-obesity medications known as GLP-1s are only one tool to combat obesity and cardiometabolic disease, they have changed the medical landscape and are clinically important in treating these diseases. Yet most Americans who have health insurance cannot get coverage for them. For some, the only option has been to resort to compounded drugs for which the Food and Drug Administration has not assured the safety, and for which the main pharmaceutical ingredient is made in Chinese chemical factories without the quality standards of FDA-approved branded drugs. Even that inferior option is going away, as the FDA has declared that the name-brand drugs are no longer in short supply and so the off-brand drugs are no longer allowed. President Trump recently called out 'the fat shot' when he told pharmaceutical companies to offer the United States the same pricing they offer other peer nations. He related a story of a friend in London who told him the price of GLP-1s there is about one-tenth of what it would cost in the U.S. The average listed price in the U.S. is more than $1,000 a month. In England, it is about $150. There is not yet legislative authority to require pharmaceutical companies to sell prescription drugs in the United States at lower prices, but there is a straightforward way that these medications can become affordable to many in the United States. Most employee health insurance coverage is through employer-sponsored plans, in which the budget is based on premiums contributed by both the employer and employee. Few plans provide coverage for any weight loss treatment, but if they did, it would have to fit in that budget — which would probably necessitate raising premiums. Toxic fat is the cause of many cardiometabolic conditions, and GLP-1 drugs can help people reclaim their health. Improving access and affordability could be transformative for public health, given that about 88% of Americans are metabolically unhealthy. Increasingly, employees are telling their employers that they want access to these medications, and many employers would like to offer plans that cover them. The brand-name manufacturers themselves provide a clue to how this could be possible. They offer their drugs directly to patients for around $500 a month. The sticking points? People whose employee-sponsored health insurance would cover even part of the cost of weight loss drugs are not eligible for that reduced price. Also, at $500 a month, even the discounted direct-to-consumer price still makes the drugs unaffordable to many. Drug pricing in the United States is not transparent, and many entities get a share of the dollars that the health plans have budgeted. Simplifying the system with the GLP-1 drugs could make these drugs more accessible. Today, a drug bought from the drug company at $1,000 can include around a $300 rebate negotiated by a pharmacy benefit manager (working on behalf of the employer-sponsored health plan) and is often accompanied by a $150 manufacturer's discount coupon. The resulting price is similar to the around $500 price that drug companies offer directly to patients who don't have coverage for these drugs. If we eliminate the rebates and coupons, so that manufacturers only charge employer-sponsored health plans the same $500 price they charge consumers directly, and then allow employers to contribute part of the cost (say $300 a month), we can get the out-of-pocket costs for employees close to the price at which these drugs are sold in other countries. It would be a rebate-free, coupon-free system with reasonable cost sharing by the employer. The only reason that system of rebates even came to exist was to create enticements so certain manufacturers could persuade pharmacy benefit managers and employee-sponsored health plans to favor their drug over others'. But in this case, where only two main drugs exist and both have publicly available clinical trial data that physicians can use to make informed prescribing decisions, rebates aren't needed. In reality, recent agreements between pharmacy benefit managers and drug manufacturers have prioritized financial interests over clinical appropriateness, determining drug preference based on what benefits the companies, not what's best for the patient. Getting the price of the drugs to an affordable level would significantly remove one of the most despised aspects of the healthcare system — prior approval authorization. Doctors' offices are expending resources to get around barriers erected to limit the use of healthcare plan dollars on expensive medications for those the insurance plan and its managers determine do not need the drug, even when the doctors believe they do. GLP-1s are highly effective for most people, but they also have some serious risks. We should leave it to doctors to make shared decisions with their patients about whether the risks outweigh the benefits. To further create incentives for the pharmaceutical companies to reduce their prices and for employers to share in the cost of these drugs, the Trump administration should agree, as the Biden administration did, to cover them under Medicare. (Trump reversed that effort this year, barring Medicare and Medicaid from using them to treat the disease of obesity.) This plan to simplify payments and expand access would not make all drugs affordable in the United States, but increasing accessibility to GLP-1s can get us on the road to eliminating the significant problem of cardiometabolic disease and improving our health. David A. Kessler, a former commissioner of the Food and Drug Administration, is the author of 'Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight.'
Yahoo
an hour ago
- Yahoo
FDA upgrades blueberry recall to highest risk level
The Food and Drug Administration (FDA) upgraded a blueberry recall this week to the highest risk level amid concerns of contamination. The FDA raised the recall of 400 boxes that weigh 30 pounds to Class I. The blueberry recall, which took place June 9, was initiated after Alma Pak International LLC of Alma, Ga. received a positive result of listeria monocytogenes during routine testing, according to the FDA. FDA's Class I classification is a 'situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.' The firm shipped the blueberries to one customer in North Carolina. The number of the recall is H-0204-2025. Listeria is a bacteria that can contaminate 'many foods,' according to the Centers for Disease Control and Prevention (CDC). People who consume those foods can be infected with the bacteria. The infections are rare, but can be serious, the CDC noted. Pregnant women, newborns, adults older than 65 years and people with weak immune systems can be especially harmed if infected, according to the CDC. The CDC estimates that 1,600 people are infected with listeria each year in the United States and 260 people die from the infection. In early February, around 2 million donuts and along with other baked goods, were recalled due to listeria contamination. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic for the treatment of R/R MM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. Lynozyfic is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Year to date, REGN's shares have lost 22.9% compared with the industry's 0.6% decline. Image Source: Zacks Investment Research The approval was based on positive results from the phase I/II LINKER-MM1 trial, wherein Lynozyfic demonstrated one of the highest objective response rates (70%) and complete response rates (45%) among bispecific antibodies for this challenging patient population. With the FDA approval, Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. MM remains the second most common blood cancer, with more than 36,000 new cases expected in the US in 2025 is tailored for patients who have undergone at least four prior treatment regimens, addressing a critical unmet need in late-stage MM. The approval strengthens REGN's oncology portfolio. Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. We note that the FDA had earlier issued a CRL for the BLA for linvoseltamab in R/R multiple myeloma. The sole approvability issue identified was related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo, indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer. REGN's oncology franchise received a boost with the European Commission's approval of odronextamab in 2024 for treating adult patients with R/R follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono. However, the company's efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its BLA for odronextamab in 2024. The FDA has accepted for review the resubmission of the BLA for odronextamab in R/R follicular lymphoma with a target action date of July 30, 2025. The successful development of these oncology drugs should be a great boost for REGN. The decline in lead drug Eylea sales is a concern for REGN. Eylea sales are under pressure due to competition from Roche's RHHBY Vabysmo. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A. The uptake of Vabysmo has been outstanding, causing a loss of market share for Eylea. REGN currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.69 to $8.81 over the past 60 days. EPS estimates for 2026 have jumped 12 cents to $9.12 during this time frame. The stock has risen 30.2% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same time frame. Year to date, shares of Bayer have surged 60%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research